9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Cisplatin, Pemetrexed, and Imatinib Mesylate in Malignant Mesothelioma

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > Cisplatin, Pemetrexed, and Imatinib Mesylate in Malignant Mesothelioma

Cisplatin, Pemetrexed, and Imatinib Mesylate in Malignant Mesothelioma

Estimated reading time: < 1 min

Condition: Mesothelioma

Estimated Enrollment: 19

Gender: All

Min Age: 18 Years

Age Group: Adult, Older Adult

Current Status: Completed

Study Results: No Results Available

Outcome Measures: Maximum Tolerated Dose (MTD) of Cisplatin, Pemetrexed, and Imatinib Mesylate Given to Participants with Unresectable or Metastatic Malignant Mesothelioma,  ,  ,

Interventions: Cisplatin, Imatinib Mesylate

Phase:

Study Type: Interventional

Study Design: Intervention Model: Single Group Assignment, Masking: None (Open Label), Primary Purpose: Treatment,

Primary Completion Date: February 2014

Completion Date: February 2014

Last  Posted Date: November 18, 2015

Location: University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Website Link: https://ClinicalTrials.gov/show/NCT00402766

Was this article helpful?
Dislike 0